Day: May 30, 2024

Global IP professionals gather to share knowledge and experiences and discuss the future of IP

BOSTON, May 30, 2024 (GLOBE NEWSWIRE) — Anaqua, the leading provider of innovation and intellectual property (IP) management technology, today announces a lineup of top-tier IP speakers and panelists for its 15^th annual Anaqua Experience Conference (AEC). The event, taking place in Boston, MA, from June 24-27, 2024, will bring together IP and business leaders from across the globe to share knowledge and experiences, and to discuss the future of IP – with a particular focus on the impact of AI in the industry.

Attendees will hear from industry experts, engage in networking events, and participate in Anaqua-led training sessions, learning new features in AQX® 11 – Anaqua’s most significant IP management platform release in 20 years – to help further optimize their IP management processes.

“This is an exciting time for the IP industry as we embrace new technologies, including AI, which could have far-reaching effects on how the industry operates,” said Bob Romeo, CEO of Anaqua. “We are proud to bring together the most innovative companies and law firms across the globe at our client conference. By connecting the entire IP community, we can move forward together to address our industry’s new issues and developments.”

Kicking off the conference is a keynote presentation from former Under Secretary of Commerce and USPTO Director David Kappos, Co-Chair of Cravath’s Intellectual Property Practice, on the macro-level trends shaping the future of IP. Other conference keynotes will delve into the specific effects of AI for IP, and will include:

• Olga V. Mack – Renowned general counsel, IP attorney, digital transformation executive, author, and Above the Law + ACC Docket Legal Tech & Future of Law columnist, discussing the increasing value of human time in the age of advanced AI.
• Stephen R. Perry – Creative Director at Bailey Brand Consulting, examining the impact of AI on the creative process and brand development.
• Panel Discussion – Exploring the balance of risks, value, and efficacy when deploying AI in IP practice, featuring Raghu Chinagudabha of Microsoft; Sunjay Mohan of SAP; and Matthew Sked of the USPTO.

“What’s always so rewarding about The Anaqua Experience Conference is watching this global community of industry professionals, who are passionate about the advancement of IP, share their thoughts, insights, and experiences in a truly collaborative and interactive environment,” said Aileen Buchanan, Vice President, Client Success of Anaqua.

The conference will also host several sessions by many IP industry leaders, including:

• Thomas H. Walls – Bausch Health Companies
• Beth McGraw – Eli Lilly and Company
• Gitte Berthelsen Lerche and Ana-Maria Macovetchi – Novo Nordisk
• Tomoe Itoh – Otsuka Pharmaceutical Co., Ltd.
• Will Federspiel – Reebok
• Elizabeth Swift – RTX Corporation
• Camylle Wnek – Techtronic Industries (TTI)

The 2024 AEC will be held at the Renaissance Boston Waterfront Hotel, starting with a welcome reception on the evening of June 24, a full day of training sessions on June 25, followed by a series of presentations and panel discussions through to June 27. Registration remains open until June 25.

To register for the event, visit https://cvent.me/RY7ZLg.

About Anaqua
Anaqua, Inc. is a premier provider of integrated intellectual property (IP) management technology solutions and services for corporations and law firms. Its IP management software solutions, AQX^® and PATTSY WAVE^®, both offer best practice workflows with big data analytics and tech-enabled services to create an intelligent environment designed to inform IP strategy, enable IP decision-making, and streamline IP operations, tailored to each segment’s need. Today, nearly half of the top 100 U.S. patent filers and global brands, as well as a growing number of law firms worldwide use Anaqua’s solutions. Over one million IP executives, attorneys, paralegals, administrators, and innovators use the platform for their IP management needs. The company’s global operations are headquartered in Boston, with offices across the U.S., Europe, Asia, and Australia. For additional information, please visit anaqua.com, or on Anaqua’s LinkedIn.

Company Contact:
Amanda Glagolev
Director, Communications
Anaqua
617-375-5808
aglagolev@anaqua.com

GlobeNewswire Distribution ID 9145896

Leverages real-world data, patient insights and a systematic process to design, operationalize and measure the effectiveness of diversity action plans in clinical trials

DURHAM, N.C., May 30, 2024 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced its comprehensive and integrated solution to improve the diversity and inclusion (D&I) of participants in clinical trials. Fortrea’s D&I solution is designed to expand patient access to participate in clinical trials and address the U.S. Food and Drug Administration (FDA) requirements, under The Food and Drug Omnibus Reform Act, to increase enrollment of underrepresented populations in clinical trials.

Fortrea’s comprehensive process integrates five components of diversity action planning and execution:

• Real-world evidence advisors research relevant real-world data sets to inform diversity planning.
• Regulatory, development and clinical operational experts design the Diversity Action Plan, validate with patient groups and negotiate with regulators.
• Operational teams access multiple data platforms, Fortrea’s Site Advisory Board and technology-enabled solutions to implement the Diversity Action Plan as an integral part of Fortrea’s clinical trial execution.
• Monitoring and reporting are enabled by Fortrea’s exclusive Diversity and Inclusion Study Insights Dashboard, providing actionable data and visualizations for ongoing study management.
• Experienced report technical writers compile data and prepare reports for regulatory submission, with ongoing regulatory support provided as part of the D&I solution.

“Clinical research that reflects a representative population provides better insight into how a potential treatment will work in a real-world setting,” said John Doyle, DrPH, president Fortrea Consulting. “Recent regulatory requirements codify progress over the last few years in biopharma’s approach to improving the inclusion of diverse populations in their development programs. Fortrea’s solution brings deep, real-world data expertise to design D&I plans that are effective and realistic, along with more than 30 years of experience across more than 20 therapeutic areas in trial execution. We also bring a steadfast commitment to D&I, not just in clinical trials but across our entire company as we pursue our purpose of bringing life-changing treatments to patients faster.”

Fortrea’s D&I solution incorporates a series of proprietary tools, including epidemiological and feasibility assessments that leverage an exclusive combination of large data sets. The solution also integrates inputs from patient groups to create insights into protocol tolerance and study conduct support requirements in different patient populations across multiple therapy areas and geographies. These insights inform global and local patient recruitment and retention plans to reach under-represented patient populations and address barriers to participation in clinical trials.

“Ensuring the inclusion of diverse patient populations in clinical trials must go beyond a plan, it takes insight and action,” said Mark Morais, chief operating officer, Fortrea. “Because of our comprehensive Voice of Patient program and our collaboration with diverse investigator sites and site networks, we have a deep understanding of what it takes to be successful in reaching populations that have traditionally been under-represented in clinical trials. At Fortrea, we are informed by real-world data, enabled by innovative technologies, and driven by our passion to deliver new therapies for all patients.”

Please visit Diversity and Inclusion in Clinical Trials on Fortrea.com for more information.

About Fortrea

Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development and patient access solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life-changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology, consulting services, differentiated technology enabled trial solutions and post-approval services.

Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in more than 90 countries is scaled to deliver focused and agile solutions to customers globally.

Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com and follow us on LinkedIn and X (formerly Twitter) @Fortrea.

Fortrea Contacts:
Fortrea Media: Galen Wilson – 703-298-0802, media@fortrea.com
Fortrea Media: Kate Dillon – 646-818-9115, kdillon@prosek.com

GlobeNewswire Distribution ID 9146130

The trading competition is to have 49 winners including a grand prize of $100,000 USD

SYDNEY, Australia, May 30, 2024 (GLOBE NEWSWIRE) — Leading online FX and CFD broker Axi has launched 2024’s biggest global trading competition, with a total prize pool of $250,000 USD.

Axi is shaking the waves, inviting traders of all sizes to trade their edge and win mega prizes, including the grand prize of $100,000 USD. Over 45 prizes will be given for ROI, top trading volume, best ROI each week, as well as five random prizes of $500 USD per week.

Registration for the competition has commenced, and the four-week contest is set to run from June 3 to June 30. Per the broker, the competition is open both for new or existing clients, and ambitious traders who are interested in participating should open or already have a live trading account with Axi, deposit a minimum of $200, and trade at least 1 lot.

Louis Cooper, Chief Commercial Officer at Axi, shares his excitement for the upcoming competition: “‘Trade Your Edge’ is our strapline, and in June we invite our traders to do just that – trade their edge on their favourite markets like Forex, Gold, Crypto, for a chance to win amazing cash prizes, including the top prize of $100,000 USD.”

This has been a very successful financial year for the broker; they’ve recently introduced cutting-edge new programmes and have also expanded their partnership portfolio to include Man City Women, LaLiga club Girona FC, and England international and six-time Premier League winner John Stones as the company’s Brand Ambassador.

To learn more about the competition and register, visit:

https://www.axi.com/int/promotions/global-trading-competition

About Axi

Axi is a global online FX and CFDs trading broker. As the preferred broker for thousands of ambitious customers in over 100 countries worldwide, we help all types of traders, trading businesses, banks and financial organizations find the edge they need to achieve their financial goals through informed transactions made on the world’s financial markets. Axi offers a comprehensive range of assets including CFDs for several asset classes such as Forex, Shares, Oil, Precious Metals, Coffee, Indices, and other commodities.

At Axi, we take pride in our reputation as an honest, fair, and responsible broker. Our numerous global awards and reviews attest to the confidence and trust we have earned from our customers who value our exceptional service, fast execution, secure payments, and easy withdrawals. Similarly, we also work pro-actively with leading regulatory governing authorities around the world to ensure that we surpass the highest industry standards.

The trading competition is only available to clients of AxiTrader Limited. CFDs carry a high risk of investment loss. Not available to AU, NZ, EU & UK residents. T&Cs apply.

For more information or additional comments from Axi, please contact: Media.Enquiries@axi.com

GlobeNewswire Distribution ID 1000963491